Pasinex Files Amended National Instrument 43-101 Technical Report for the Pinargozu Mine
TORONTO, Jan. 30, 2019 (GLOBE NEWSWIRE) — Pasinex Resources Limited (CSE: PSE) (FSE: PNX) (“the Company”) announces that it has […]
GasLog Partners LP Reports Financial Results for the Three-Month Period and the Year Ended December 31, 2018, Increases Cash Distribution and Announces Unit Repurchase Programme
Monaco, Jan. 30, 2019 (GLOBE NEWSWIRE) — GasLog Partners LP (“GasLog Partners” or the “Partnership”) (NYSE: GLOP), an international owner […]
ScottsMiracle-Gro Reports Strong First Quarter Sales; U.S. Consumer Sales Increase 9%; Acquisitions Push Hawthorne Up 84%
GAAP loss from continuing operations per share of $1.49 vs. $0.35 in prior year Non-GAAP adjusted loss per share of […]
uniQure to Participate in Multiple Upcoming Industry Conferences
~ Company to Host Investor Call on Friday, February 8, 2019 at 8:30 a.m. ET to Discuss Updated Clinical Data […]
Nasdaq Reports Fourth Quarter and Full Year 2018 Results; Delivers Strong Revenue Growth in 2018
2018 net revenues1 were $2,526 million, an increase of 5% compared to 2017, resulting from 8% organic growth partially offset […]
Nasdaq Announces Quarterly Dividend of $0.44 Per Share
NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) — The Board of Directors of Nasdaq, Inc. (Nasdaq: NDAQ) has declared a […]
Trevena Announces $10 Million Registered Direct Offering of Common Stock
CHESTERBROOK, Pa., Jan. 30, 2019 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN) (the “Company”) today announced that it entered into […]
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
Topline results anticipated in 2Q 2019 NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a […]
Kamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development
REHOVOT, Israel, Jan. 30, 2019 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced […]
Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
MIST-1 study met primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, high tolerability; Study further validates OpteJet™ platform […]
